Next Gen Liquicore Prime -Rapid NGS
NextGen Liquicore Prime Panel by Rapid NGS, Peripheral Blood* Price
What is a NextGen Liquicore Prime?
NextGen Liquicore Prime is an advanced liquid biopsy test that uses next-generation sequencing (NGS) to analyse your blood for genetic changes in cancer-related genes. This sophisticated test examines circulating tumour DNA in your bloodstream to identify specific genetic mutations, fusions, and alterations across 50 key cancer-driving genes.
The test helps doctors personalise your cancer treatment by identifying which targeted therapies might work best for your specific genetic profile.
What does the NextGen Liquicore Prime measure?
This comprehensive test evaluates several important genetic features that guide cancer treatment decisions:
- Genetic mutations - Identifies specific changes in genes that may drive cancer growth or affect treatment response.
• Gene fusions - Detects when parts of different genes join together abnormally, creating new cancer-driving proteins.
• Copy number variations - Measures when genes are amplified (too many copies) or deleted, affecting protein production.
• Targeted therapy markers - Identifies genetic changes that predict response to specific cancer medicines.
• Treatment resistance patterns - Detects mutations that may cause resistance to certain therapies.
• Disease monitoring markers - Tracks genetic changes that help monitor treatment progress and detect recurrence.
NextGen Liquicore Prime: Who Needs It and Why It's Done
What Symptoms May Call for a NextGen Liquicore Prime?
Your doctor may recommend this test if you experience symptoms related to solid tumours, particularly lung cancer:
- Persistent cough that doesn't improve or worsens over time
• Shortness of breath or difficulty breathing during normal activities
• Chest pain that may worsen with deep breathing or coughing
• Hoarseness or voice changes lasting more than two weeks
• Coughing up blood or rust-coloured sputum
Who should get a NextGen Liquicore Prime?
This NGS sequencing test is recommended for specific patient groups who can benefit from personalized cancer treatment:
- Patients diagnosed with solid tumours, especially lung cancer, colorectal cancer, breast cancer, or melanoma.
• Individuals whose cancer has spread (metastasized) and need targeted therapy options. - Patients for whom tissue biopsy is technically challenging or poses severe health risk.
• Patients who haven't responded well to standard chemotherapy treatments.
• Those considering participation in clinical trials for new cancer treatments.
• Patients whose cancer has returned after initial treatment.
• Individuals with family history of cancer seeking personalized treatment guidance.
Why is a NextGen Liquicore Prime done?
This test helps doctors choose the most effective targeted therapies for your specific cancer type based on your unique genetic profile. By identifying actionable genetic alterations, it enables personalized treatment approaches that can improve outcomes and reduce unnecessary side effects from treatments that may not work for your particular cancer.
Importance of a NextGen Liquicore Prime
The NextGen Liquicore Prime test represents a significant advancement in personalized cancer care. This liquid biopsy approach offers a less invasive alternative to tissue biopsies while providing comprehensive genetic profiling of your cancer. By analysing circulating tumour DNA in your blood, the test can identify specific genetic alterations that guide treatment decisions, helping your healthcare team select targeted therapies most likely to be effective for your cancer.
The test's ability to detect multiple types of genetic changes (including mutations, fusions, and copy number variations) provides a complete picture of your cancer's genetic landscape. This information is crucial for accessing FDA-approved targeted therapies, identifying clinical trial opportunities, and monitoring treatment response. Early identification of resistance mutations also helps doctors adjust treatment strategies before cancer progresses.
NextGen Liquicore Prime Booking & Reports – Metropolis Healthcare India
How to Book a NextGen Liquicore Prime?
- Simple Online Booking
Booking can be done through the Metropolis Healthcare App or website. Select the NextGen Liquicore Prime, choose a convenient time slot, and provide your address for a blood test at home. You can also visit the nearest Metropolis Lab if you prefer to give the sample directly at the lab.
- Safe Home Sample Collection
Our trained phlebotomists ensure the timely collection of your sample while strictly following all safety and hygiene protocols.
- Sample Tracking Updates
Stay informed at every step. From collection to testing, you can track your sample directly through the Metropolis Healthcare website.
- Accurate Laboratory Testing
Your sample is processed at our NABL & CAP accredited laboratories, where expert technicians ensure accurate results.
- Quick & Easy Reports
Receive your test reports promptly via email, WhatsApp, or by downloading them directly from the Metropolis Healthcare website or app.
Is home blood sample collection for NextGen Liquicore Prime available near you?
Yes, Metropolis Healthcare provides home blood sample collection for the NextGen Liquicore Prime Test. Our trained phlebotomists follow strict safety protocols while collecting your blood sample in the comfort of your home. This service eliminates the need for travel, especially important for cancer patients who may have compromised immunity or mobility challenges.
How Long Does It Take to Get a NextGen Liquicore Prime Report?
Reports are usually available after 5 days once the sample reaches the lab.
Note: Reporting time may vary depending on your location.
Where can I see or get NextGen Liquicore Prime results?
Test results from Metropolis Healthcare can be accessed through multiple convenient channels. You can log in to the Metropolis website using your credentials or use the Metropolis Healthcare App to view and download your reports. Additionally, test reports are sent via email or WhatsApp and you also have the option to collect a physical copy directly from the lab.
Interpreting NextGen Liquicore Prime Results
The following table explains how your NextGen Liquicore Prime results are interpreted and their clinical significance:
|
Parameters |
Result Type |
Clinical Significance |
|
EGFR Mutations (e.g., Exon 19 deletion) |
Detected/Not Detected |
When detected, indicates potential response to EGFR-targeted therapies like Afatinib, Erlotinib, Gefitinib, or Osimertinib |
|
TP53 Mutations |
Detected/Not Detected |
When detected, may indicate more aggressive cancer behaviour and influence treatment planning |
|
EGFR Amplification |
CNV Ratio |
Elevated ratios may suggest potential response to certain targeted therapies in specific cancer types |
|
Gene Fusions (ALK, ROS1, NTRK) |
Detected/Not Detected |
When detected, indicates availability of specific targeted therapies |
|
Molecular Frequency |
Percentage |
Shows the proportion of cancer cells carrying specific mutations, helping assess tumour burden |
|
Variant Classification |
Tier 1-4 |
Tier 1 indicates strong clinical significance for therapy selection |
Conditions that May Affect NextGen Liquicore Prime Accuracy
Several factors can influence your NextGen Liquicore Prime results and should be discussed with your oncologist:
- Recent cancer treatments, including chemotherapy or radiation therapy, may temporarily affect circulating tumour DNA levels.
- Blood transfusions within the past few weeks can dilute your sample and affect detection sensitivity.
- Certain medications that affect DNA integrity or blood composition may impact results.
- Active infections or inflammatory health conditions can sometimes interfere with genetic analysis.
- Sample collection timing - ideally collected 3 weeks after completion of therapy for optimal results.
- Haemolysis (breakdown of red blood cells) during collection can compromise sample quality.
- Very low tumour burden may result in insufficient circulating tumour DNA for detection.
How is a NextGen Liquicore Prime Done?
The NextGen Liquicore Prime follows a systematic process to ensure accurate genetic analysis:
- A healthcare professional cleanses the area on your arm, typically the inside of your elbow.
- A tourniquet is applied to make your veins more visible and accessible.
- A sterile needle is gently inserted into the vein to collect blood.
- Three Streck BCT tubes are filled with 9-9.5 ml of blood each, avoiding overfilling to prevent haemolysis.
- The samples are carefully labelled and stored at appropriate temperature conditions.
- Your blood samples are transported to our NABL and CAP accredited molecular pathology lab.
- Advanced next-generation sequencing technology analyses the circulating tumour DNA for genetic alterations.
- Expert pathologists interpret the results and prepare your comprehensive genetic profile report.
How Should You Prepare for a NextGen Liquicore Prime?
Preparing for your NextGen Liquicore Prime test is straightforward and requires minimal preparation:
- No fasting required - You can eat and drink normally before the test.
- Take medications as usual - Continue your regular medicines unless specifically advised otherwise by your doctor.
- Provide complete clinical history - Ensure your healthcare provider has detailed information about your cancer diagnosis.
- Medication review - Inform your doctor about all current treatments, especially cancer therapies, chemotherapy, or targeted drugs.
- Schedule appropriately - The test is ideally done 3 weeks after completing cancer therapy for optimal results.
- Wear comfortable clothing - Choose clothing that allows easy access to your arm for blood collection.
Diseases that a NextGen Liquicore Prime Can Help Detect
This comprehensive genetic test assists in the diagnosis and management of various solid tumours:
- Lung cancer - Particularly non-small cell lung cancer (NSCLC) with EGFR, ALK, ROS1, and other targetable mutations.
- Colorectal cancer - Including tumours with KRAS, BRAF, and PIK3CA alterations affecting treatment choices.
- Breast cancer - Especially cases with ERBB2 (HER2), PIK3CA, and hormone receptor pathway changes.
- Melanoma - Including tumours with BRAF, NRAS, and KIT mutations that respond to targeted therapies.
- Gastric and oesophageal cancers - With ERBB2, FGFR, and other actionable genetic alterations.
- Head and neck cancers - Particularly those with EGFR and other targetable genetic changes.
- Endometrial cancers - Including cases with PIK3CA, PTEN, and mismatch repair gene alterations.
NextGen Liquicore Prime/Packages that You Can Book With Metropolis Healthcare
Metropolis Healthcare offers comprehensive cancer genetic testing options to support your personalised treatment journey:
|
Test/Package Name |
Purpose/Highlights |
|
Targeted genetic analysis specifically for lung cancer with key actionable mutations |
|
|
Extensive genetic profiling using tissue samples for comprehensive cancer analysis |
|
|
Measures overall genetic changes to predict immunotherapy response |
Frequently asked questions
Find quick answers to the most common questions about health tests, bookings, and reports.
Regular exercise, a balanced diet, avoiding smoking, maintaining a healthy weight, and managing stress all help reduce heart disease risk.
Common signs include irritability, trouble sleeping, headaches, difficulty concentrating, and muscle tension.
Ratings & Reviews
We're satisfying our customers every day since 1980.
Choose precision On time, every time!
- 98% on time collections with a 60 minutes promise
- Real-time tracking of phlebotomist arrival and report generation
- Fully digital report delivery—view from mobile or desktop instantly
- Continuous monitoring of turnaround times to ensure accuracy and speed
- Dedicated support team to resolve any delays or queries quickly
Why Metropolis Healthcare?
Metropolis has been present for over 40 years in the market.
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
0
Years of experience
170+
Advanced Labs
Trusted by
Leading Doctors & Hospitals
2,000+
Scientific Officers
Proficiency Testing
for Accurate Reports
Latest Blogs & News
Stay informed with our expert insights and updates.
About Us
Metropolis Healthcare is a leading diagnostic service provider in India. We are a team of dedicated professionals committed to ensuring you and your family receive the most accurate and timely healthcare solutions. We believe in making health care accessible, affordable and evidence-based. Our expert panel are equipped with the latest technology and manned by a certified team of over 4000+ technicians.
In diagnostic services, we have more than three decades of experience servicing diverse stakeholders health advantage packages for men, women and seniors, genetic fitness & corporation in over 650+ tests like Oncology, Neurology, Gynaecology, Haematology, and many more. Our diagnostic services are located in leading doctors and clinics and serve over 15+ cities in India.